Understanding meningococcal X unconjugated saccharide behaviour in monovalent and pentavalent (A, C, Y, W and X) conjugate formulations for quality analysis of meningococcal conjugate vaccine.

IF 2.5 3区 化学 Q3 BIOCHEMISTRY & MOLECULAR BIOLOGY
Swapnil Phugare, Abhijit Patil, Sameer Kale, Pankaj Sharma, Sunil Kumar Goel, Sunil Gairola
{"title":"Understanding meningococcal X unconjugated saccharide behaviour in monovalent and pentavalent (A, C, Y, W and X) conjugate formulations for quality analysis of meningococcal conjugate vaccine.","authors":"Swapnil Phugare, Abhijit Patil, Sameer Kale, Pankaj Sharma, Sunil Kumar Goel, Sunil Gairola","doi":"10.1016/j.carres.2025.109678","DOIUrl":null,"url":null,"abstract":"<p><p>The pentavalent meningococcal polysaccharide conjugate vaccine, which includes serogroup A, C, Y, W, and X, has recently been prequalified by the WHO and is currently the only vaccine available against serogroup X. The amount of free saccharide in conjugate vaccines is a crucial factor that directly impacts the stability and immunogenicity of the vaccine. Therefore, precise estimation of free saccharide content is particularly important in multivalent conjugate vaccines. This study focuses on the development of conditions for estimating free saccharide in monovalent meningococcal X conjugate bulk. Accuracies were demonstrated at 5 %, 10 %, 25 %, and 40 % of the test specification, with recoveries ranging from 70 to 130 %. Repeatability analysis showed intra-assay variation ranging from 2 to 6 %, while inter-assay variation ranged from 2 to 14 %. Specificity studies indicated that there was no interference from assay components such as sample excipients, DOC, or acids. When these established conditions were applied to the finished product for free saccharide estimation, an interesting observation was noted. It was found that the unconjugated meningococcal X saccharide interacted with other biomolecules present in the vaccine formulation, leading to decreased free saccharide recovery for serogroup X. It is believed that aggregation, possibly due to carrier proteins (TT and CRM) and/or associated polysaccharides, may be responsible for trapping the free saccharide from serogroup X. Efforts were made to control these biomolecular interactions by adjusting solubilities, buffering, and physico-chemical conditions to separate free saccharide. Phosphate buffers, ionic-nonionic detergent solutions, salt buffers, and 32 biomolecule formulations were explored in various combinations before identifying the root cause for the decreased X free saccharide recoveries.</p>","PeriodicalId":9415,"journal":{"name":"Carbohydrate Research","volume":"558 ","pages":"109678"},"PeriodicalIF":2.5000,"publicationDate":"2025-09-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Carbohydrate Research","FirstCategoryId":"92","ListUrlMain":"https://doi.org/10.1016/j.carres.2025.109678","RegionNum":3,"RegionCategory":"化学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"BIOCHEMISTRY & MOLECULAR BIOLOGY","Score":null,"Total":0}
引用次数: 0

Abstract

The pentavalent meningococcal polysaccharide conjugate vaccine, which includes serogroup A, C, Y, W, and X, has recently been prequalified by the WHO and is currently the only vaccine available against serogroup X. The amount of free saccharide in conjugate vaccines is a crucial factor that directly impacts the stability and immunogenicity of the vaccine. Therefore, precise estimation of free saccharide content is particularly important in multivalent conjugate vaccines. This study focuses on the development of conditions for estimating free saccharide in monovalent meningococcal X conjugate bulk. Accuracies were demonstrated at 5 %, 10 %, 25 %, and 40 % of the test specification, with recoveries ranging from 70 to 130 %. Repeatability analysis showed intra-assay variation ranging from 2 to 6 %, while inter-assay variation ranged from 2 to 14 %. Specificity studies indicated that there was no interference from assay components such as sample excipients, DOC, or acids. When these established conditions were applied to the finished product for free saccharide estimation, an interesting observation was noted. It was found that the unconjugated meningococcal X saccharide interacted with other biomolecules present in the vaccine formulation, leading to decreased free saccharide recovery for serogroup X. It is believed that aggregation, possibly due to carrier proteins (TT and CRM) and/or associated polysaccharides, may be responsible for trapping the free saccharide from serogroup X. Efforts were made to control these biomolecular interactions by adjusting solubilities, buffering, and physico-chemical conditions to separate free saccharide. Phosphate buffers, ionic-nonionic detergent solutions, salt buffers, and 32 biomolecule formulations were explored in various combinations before identifying the root cause for the decreased X free saccharide recoveries.

了解单价和五价(A、C、Y、W和X)脑膜炎球菌X非偶联糖的行为,用于脑膜炎球菌结合疫苗的质量分析。
五价脑膜炎球菌多糖结合疫苗包括A、C、Y、W和X血清群,最近已通过世卫组织的资格预审,是目前唯一可用的针对X血清群的疫苗。结合疫苗中游离糖的含量是直接影响疫苗稳定性和免疫原性的关键因素。因此,精确估计游离糖含量在多价结合疫苗中尤为重要。本研究的重点是建立估计单价脑膜炎球菌X结合体游离糖的条件。准确度分别为测试标准的5%、10%、25%和40%,回收率为70%至130%。重复性分析显示,组内变异范围为2 ~ 6%,组间变异范围为2 ~ 14%。特异性研究表明,没有干扰的分析成分,如样品辅料,DOC,或酸。当这些既定的条件应用于成品游离糖的估计,一个有趣的观察被注意到。研究发现,未结合的脑膜炎球菌X糖与疫苗制剂中存在的其他生物分子相互作用,导致血清X的游离糖回收率下降。据认为,可能是由于载体蛋白(TT和CRM)和/或相关多糖的聚集,可能是导致血清X游离糖被捕获的原因。以及分离游离糖的物理化学条件。在确定X游离糖回收率下降的根本原因之前,研究人员探索了磷酸盐缓冲液、离子-非离子洗涤剂溶液、盐缓冲液和32种生物分子配方的各种组合。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
Carbohydrate Research
Carbohydrate Research 化学-生化与分子生物学
CiteScore
5.00
自引率
3.20%
发文量
183
审稿时长
3.6 weeks
期刊介绍: Carbohydrate Research publishes reports of original research in the following areas of carbohydrate science: action of enzymes, analytical chemistry, biochemistry (biosynthesis, degradation, structural and functional biochemistry, conformation, molecular recognition, enzyme mechanisms, carbohydrate-processing enzymes, including glycosidases and glycosyltransferases), chemical synthesis, isolation of natural products, physicochemical studies, reactions and their mechanisms, the study of structures and stereochemistry, and technological aspects. Papers on polysaccharides should have a "molecular" component; that is a paper on new or modified polysaccharides should include structural information and characterization in addition to the usual studies of rheological properties and the like. A paper on a new, naturally occurring polysaccharide should include structural information, defining monosaccharide components and linkage sequence. Papers devoted wholly or partly to X-ray crystallographic studies, or to computational aspects (molecular mechanics or molecular orbital calculations, simulations via molecular dynamics), will be considered if they meet certain criteria. For computational papers the requirements are that the methods used be specified in sufficient detail to permit replication of the results, and that the conclusions be shown to have relevance to experimental observations - the authors'' own data or data from the literature. Specific directions for the presentation of X-ray data are given below under Results and "discussion".
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信